Advertisement

Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Incretin combination therapy: a breakthrough for type 2 diabetes?

With unmet needs remaining in type 2 diabetes, pharmaceutical companies are becoming more experimental when developing new treatments. One trend includes combining drugs in one class to determine if they are more efficacious than one drug alone. This trend has been applied to incretins, GLP-1 and GIP, with Eli Lilly recently publishing positive results for its drug candidate LY3298176.

Download our 2018 Technology, Media & Telecoms Predictions worth over $5,000 for free

Close
Close
Close

Go Top